Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples2022-12-29T21:22:21-08:00November 15th, 2022|Read more
LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients2022-12-29T21:19:31-08:00June 4th, 2022|Read more
Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?2023-01-08T18:20:36-08:00May 30th, 2022|Read more
Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma2022-09-07T22:22:23-07:00May 3rd, 2022|Read more
Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients2022-01-06T05:38:03-08:00January 4th, 2022|Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States2025-08-26T08:11:34-07:00May 19th, 2020|Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.2021-02-26T19:10:05-08:00May 12th, 2020|Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay2021-11-14T22:08:08-08:00December 5th, 2019|Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA2021-02-26T19:10:37-08:00June 19th, 2019|Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies2021-02-26T19:10:45-08:00May 21st, 2019|Read more
Lymphoma, Leukemia and Myeloma Congress Oct 13-16, 2026 New York, NY Attending Visit Conference Website
